Nine months of treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 appears to have slowed disease progression relative to its natural course in people with early-stage Huntington’s disease. That’s according to new interim data from a substudy, or Part C (ACTRN12624000602527), of an Australia-based Phase 1 clinical trial…